Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: An analysis from the cardiac risk factors in childhood cancer survivors study

David C. Landy, Tracie L Miller, Stuart R. Lipsitz, Gabriela Lopez-Mitnik, Andrea S. Hinkle, Louis S. Constine, M. Jacob Adams, Steven E Lipshultz

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Anthracycline-treated childhood cancer survivors experience cardiac damage that results in decreased left ventricular (LV) mass, leading to increased LV wall stress, which underlies their greater risk of cardiomyopathy. Many of these survivors also are at risk of growth hormone (GH) abnormalities from cranial irradiation exposure, although it is unknown whether such exposure is associated with cardiotoxicity. Echocardiograms and insulin-like growth factor-1 (IGF-1), a marker of GH, were measured in 130 anthracycline-treated childhood cancer survivors, 59 of whom had been exposed to cranial irradiation, a mean 10 years after their cancer diagnosis. Echocardiographic parameters and IGF-1 were standardized relative to age or body surface area using data from sibling control subjects and expressed as the percentage difference from normal values. The results showed that after adjustment for other risk factors, survivors exposed to cranial irradiation had an additional 12 % decrease in LV mass compared with unexposed survivors (P < 0.01) and an additional 3.6 % decrease in LV dimension (P = 0.03). Survivors exposed to cranial irradiation also had a 30.8 % decrease in IGF-1 relative to normal values, which was greater than the 10.5 % decrease in unexposed survivors (P < 0.01). The above findings led us to conclude that in anthracycline-treated childhood cancer survivors a mean 10 years after their diagnosis, those with cranial irradiation exposure had significantly greater decreases in LV mass and dimension. Because cranial irradiation also was associated with decreased IGF-1, it is possible that GH deficiencies mediated this effect, suggesting that GH replacement therapy may help to prevent the development of cardiotoxicity.

Original languageEnglish
Pages (from-to)826-834
Number of pages9
JournalPediatric Cardiology
Volume34
Issue number4
DOIs
StatePublished - Apr 1 2013

Fingerprint

Cranial Irradiation
Anthracyclines
Somatomedins
Growth Hormone
Neoplasms
Reference Values
Body Surface Area
Hormone Replacement Therapy
Cardiomyopathies
Cardiotoxicity

Keywords

  • Anthracyclines
  • Cancer
  • Cardiomyopathy
  • Cranial irradiation
  • Survivors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors : An analysis from the cardiac risk factors in childhood cancer survivors study. / Landy, David C.; Miller, Tracie L; Lipsitz, Stuart R.; Lopez-Mitnik, Gabriela; Hinkle, Andrea S.; Constine, Louis S.; Adams, M. Jacob; Lipshultz, Steven E.

In: Pediatric Cardiology, Vol. 34, No. 4, 01.04.2013, p. 826-834.

Research output: Contribution to journalArticle

Landy, David C. ; Miller, Tracie L ; Lipsitz, Stuart R. ; Lopez-Mitnik, Gabriela ; Hinkle, Andrea S. ; Constine, Louis S. ; Adams, M. Jacob ; Lipshultz, Steven E. / Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors : An analysis from the cardiac risk factors in childhood cancer survivors study. In: Pediatric Cardiology. 2013 ; Vol. 34, No. 4. pp. 826-834.
@article{882e78ad5cc1463fadd063e865630b78,
title = "Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: An analysis from the cardiac risk factors in childhood cancer survivors study",
abstract = "Anthracycline-treated childhood cancer survivors experience cardiac damage that results in decreased left ventricular (LV) mass, leading to increased LV wall stress, which underlies their greater risk of cardiomyopathy. Many of these survivors also are at risk of growth hormone (GH) abnormalities from cranial irradiation exposure, although it is unknown whether such exposure is associated with cardiotoxicity. Echocardiograms and insulin-like growth factor-1 (IGF-1), a marker of GH, were measured in 130 anthracycline-treated childhood cancer survivors, 59 of whom had been exposed to cranial irradiation, a mean 10 years after their cancer diagnosis. Echocardiographic parameters and IGF-1 were standardized relative to age or body surface area using data from sibling control subjects and expressed as the percentage difference from normal values. The results showed that after adjustment for other risk factors, survivors exposed to cranial irradiation had an additional 12 {\%} decrease in LV mass compared with unexposed survivors (P < 0.01) and an additional 3.6 {\%} decrease in LV dimension (P = 0.03). Survivors exposed to cranial irradiation also had a 30.8 {\%} decrease in IGF-1 relative to normal values, which was greater than the 10.5 {\%} decrease in unexposed survivors (P < 0.01). The above findings led us to conclude that in anthracycline-treated childhood cancer survivors a mean 10 years after their diagnosis, those with cranial irradiation exposure had significantly greater decreases in LV mass and dimension. Because cranial irradiation also was associated with decreased IGF-1, it is possible that GH deficiencies mediated this effect, suggesting that GH replacement therapy may help to prevent the development of cardiotoxicity.",
keywords = "Anthracyclines, Cancer, Cardiomyopathy, Cranial irradiation, Survivors",
author = "Landy, {David C.} and Miller, {Tracie L} and Lipsitz, {Stuart R.} and Gabriela Lopez-Mitnik and Hinkle, {Andrea S.} and Constine, {Louis S.} and Adams, {M. Jacob} and Lipshultz, {Steven E}",
year = "2013",
month = "4",
day = "1",
doi = "10.1007/s00246-012-0539-6",
language = "English",
volume = "34",
pages = "826--834",
journal = "Pediatric Cardiology",
issn = "0172-0643",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors

T2 - An analysis from the cardiac risk factors in childhood cancer survivors study

AU - Landy, David C.

AU - Miller, Tracie L

AU - Lipsitz, Stuart R.

AU - Lopez-Mitnik, Gabriela

AU - Hinkle, Andrea S.

AU - Constine, Louis S.

AU - Adams, M. Jacob

AU - Lipshultz, Steven E

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Anthracycline-treated childhood cancer survivors experience cardiac damage that results in decreased left ventricular (LV) mass, leading to increased LV wall stress, which underlies their greater risk of cardiomyopathy. Many of these survivors also are at risk of growth hormone (GH) abnormalities from cranial irradiation exposure, although it is unknown whether such exposure is associated with cardiotoxicity. Echocardiograms and insulin-like growth factor-1 (IGF-1), a marker of GH, were measured in 130 anthracycline-treated childhood cancer survivors, 59 of whom had been exposed to cranial irradiation, a mean 10 years after their cancer diagnosis. Echocardiographic parameters and IGF-1 were standardized relative to age or body surface area using data from sibling control subjects and expressed as the percentage difference from normal values. The results showed that after adjustment for other risk factors, survivors exposed to cranial irradiation had an additional 12 % decrease in LV mass compared with unexposed survivors (P < 0.01) and an additional 3.6 % decrease in LV dimension (P = 0.03). Survivors exposed to cranial irradiation also had a 30.8 % decrease in IGF-1 relative to normal values, which was greater than the 10.5 % decrease in unexposed survivors (P < 0.01). The above findings led us to conclude that in anthracycline-treated childhood cancer survivors a mean 10 years after their diagnosis, those with cranial irradiation exposure had significantly greater decreases in LV mass and dimension. Because cranial irradiation also was associated with decreased IGF-1, it is possible that GH deficiencies mediated this effect, suggesting that GH replacement therapy may help to prevent the development of cardiotoxicity.

AB - Anthracycline-treated childhood cancer survivors experience cardiac damage that results in decreased left ventricular (LV) mass, leading to increased LV wall stress, which underlies their greater risk of cardiomyopathy. Many of these survivors also are at risk of growth hormone (GH) abnormalities from cranial irradiation exposure, although it is unknown whether such exposure is associated with cardiotoxicity. Echocardiograms and insulin-like growth factor-1 (IGF-1), a marker of GH, were measured in 130 anthracycline-treated childhood cancer survivors, 59 of whom had been exposed to cranial irradiation, a mean 10 years after their cancer diagnosis. Echocardiographic parameters and IGF-1 were standardized relative to age or body surface area using data from sibling control subjects and expressed as the percentage difference from normal values. The results showed that after adjustment for other risk factors, survivors exposed to cranial irradiation had an additional 12 % decrease in LV mass compared with unexposed survivors (P < 0.01) and an additional 3.6 % decrease in LV dimension (P = 0.03). Survivors exposed to cranial irradiation also had a 30.8 % decrease in IGF-1 relative to normal values, which was greater than the 10.5 % decrease in unexposed survivors (P < 0.01). The above findings led us to conclude that in anthracycline-treated childhood cancer survivors a mean 10 years after their diagnosis, those with cranial irradiation exposure had significantly greater decreases in LV mass and dimension. Because cranial irradiation also was associated with decreased IGF-1, it is possible that GH deficiencies mediated this effect, suggesting that GH replacement therapy may help to prevent the development of cardiotoxicity.

KW - Anthracyclines

KW - Cancer

KW - Cardiomyopathy

KW - Cranial irradiation

KW - Survivors

UR - http://www.scopus.com/inward/record.url?scp=84879504038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879504038&partnerID=8YFLogxK

U2 - 10.1007/s00246-012-0539-6

DO - 10.1007/s00246-012-0539-6

M3 - Article

C2 - 23080542

AN - SCOPUS:84879504038

VL - 34

SP - 826

EP - 834

JO - Pediatric Cardiology

JF - Pediatric Cardiology

SN - 0172-0643

IS - 4

ER -